DGX
Quest Diagnostics
September 10, 2026 · intraday
- Rarity
- 1.02
- Peak move
- −2.61%
- Float cap
- $25.8B
Quest Diagnostics provides diagnostic information services through laboratory testing, offering insights from clinical lab results to help physicians, hospitals, patients, consumers, health plans, government agencies, employers, and other healthcare organizations improve health outcomes. It operates patient service centers, laboratory facilities, and consumer-initiated testing through QuestHealth.com. The company serves about half of U.S. physicians and hospitals annually.
Where do you see this going?
no votes yetVoting closed at 4:00 PM ET.
What we found
5 events · 0 from SEC or newswire · 0 timed with the moveanalyst_ratingZacks Research raised its Q3 2026 EPS estimate for Quest Diagnostics to $2.83 from $2.82, keeping full-year 2026 EPS at $11.15 and FY2027 at $11.73.
peer_disclosureLabcorp held its investor day on Sept. 10, 2026, with CEO Adam Schechter presenting a long-term financial framework; Labcorp's last quarter showed revenue of $3.73 billion, up 5.8%, and full-year adjusted EPS guidance of $18.10-$18.55.
product_launchQuest Diagnostics announced that U.S. Apple Health app users will be able to buy a Quest lab panel covering more than 50 biomarkers for $119 in the iPhone and iPad app later this year, with blood draws at about 2,000 Quest patient service centers and results returned in the app; Apple unveiled the update at its September event.
insider_saleQuest Diagnostics Chairman, CEO and President Jim Davis sold 10,000 shares at $242.72 for about $2.4 million on September 1, 2026 under a pre-arranged Rule 10b5-1 trading plan, leaving him 122,423 shares directly held, per a Form 4.
analyst_ratingUBS raised its price target on Quest Diagnostics to $245 from $232 while keeping a Neutral rating, after hosting CFO Sam Samad and investor-relations VP Damini Chokshi at investor meetings, and flagged up to about $100 million of risk from PAMA reimbursement cuts.